Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2015 05:30 ET | Source: Genetic Technologies

Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R)

MELBOURNE, AUSTRALIA--(Marketwired - Jan 29, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to report that up to 6 new breast...
January 21, 2015 18:27 ET | Source: Genetic Technologies

Genetic Technologies Secures A$24 Million Standby Equity Placement Facility

MELBOURNE, AUSTRALIA--(Marketwired - Jan 21, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Genetic Technologies" or the "Company") today announced...
December 17, 2014 05:30 ET | Source: Genetic Technologies

Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment

MELBOURNE, AUSTRALIA--(Marketwired - Dec 17, 2014) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announces that findings from a new research...
November 12, 2014 13:24 ET | Source: Neuren Pharmaceuticals

Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial

BETHESDA, MD--(Marketwired - Nov 12, 2014) - Highlights: Achieved primary endpoint -- both dose levels of NNZ-2566 were well tolerated after 28 days of treatment and...
November 10, 2014 17:13 ET | Source: Alchemia

Alchemia Announces Departure of Chief Executive Officer

BRISBANE, AUSTRALIA--(Marketwired - Nov 10, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the departure of Thomas Liquard as Chief Executive...
October 26, 2014 18:28 ET | Source: Alchemia

Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer

BRISBANE, AUSTRALIA--(Marketwired - Oct 26, 2014) - Alchemia Limited (ASX: ACL) Summary: Phase III trial does not reach primary endpoint of statistically...
October 09, 2014 20:12 ET | Source: Alchemia

Alchemia Announces Database Lock of Its HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer

BRISBANE, AUSTRALIA--(Marketwired - Oct 9, 2014) - Alchemia Limited (ASX: ACL) Database lock triggers commencement of primary endpoint analysis 350...
October 06, 2014 05:30 ET | Source: Genetic Technologies

Genetic Technologies Announces Quarterly BREVAGen(TM) Results

MELBOURNE, AUSTRALIA--(Marketwired - Oct 6, 2014) - Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") reported 942 BREVAGen™ test samples...
October 01, 2014 05:30 ET | Source: Genetic Technologies

Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test

MELBOURNE, AUSTRALIA--(Marketwired - Oct 1, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use...
September 24, 2014 05:30 ET | Source: Genetic Technologies

Genetic Technologies Announces Appointment of Independent Non-Executive Directors

MELBOURNE, AUSTRALIA--(Marketwired - Sep 24, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have...